AHA registry to aggregate data, research on COVID-19 and CVD
Click Here to Manage Email Alerts
The American Heart Association announced it is developing a novel registry for the organization and aggregation of data, research, treatment protocols for COVID-19 and risk factors tied to related adverse CV outcomes.
Beginning in May, the AHA’s free COVID-19 CVD registry, powered by its Get With The Guidelines hospital quality improvement program, will be made available to more than 2,400 hospitals currently participating in the program module.
Additionally, aggregate data will be made available for researchers through the AHA’s Institute for Precision Cardiovascular Medicine.
”Having sufficient data is the first step to understanding the impact of COVID-19 on cardiovascular health,“ John Warner, MD, FAHA, chair of the quality oversight committee, past president of the AHA and executive vice president for Health System Affairs at the University of Texas Southwestern Health System, said in a press release. “As a trusted resource for data and research, with an entry point in more than 2,400 U.S. hospitals, the American Heart Association is uniquely positioned to gather data quickly and accurately.”
While the literature has identified patients with COVID-19 who also presented with or subsequently developed conditions such as HF, cardiogenic shock, stroke or arrhythmias, the data have not been collected in a structured manner, the AHA wrote in the release. Therefore, the registry will collect biomarkers, clinical data and CV outcomes in patients with COVID-19, according to the release.
Disclosures: Warner reports no relevant financial disclosures.
Collapse
Read more about
Click Here to Manage Email Alerts